> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Accelerated Approval Faces Scrutiny After Cancer Drug Review
- URL: https://www.fdaweb.com/accelerated-approval-faces-scrutiny-after-cancer-drug-review/
- Published: 2025-04-03T12:00:00.000Z
- Updated: 2026-09-14T14:56:55.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158953

FDA’s accelerated approval program is under renewed scrutiny after a recent *JAMA* [study](https://jamanetwork.com/journals/jamaoncology/fullarticle/2831931?guestAccessKey=1039c841-004a-4510-b5ff-18b8b8fe1094&utm%5Fsource=silverchair&utm%5Fmedium=email&utm%5Fcampaign=article%5Falert-jamaoncology&utm%5Fcontent=olf&utm%5Fterm=040325&adv=000000733514) highlighted concerns about cancer drugs that remain available despite failing to show clinical benefit in confirmatory trials. The program allows drug companies to bring medications for serious conditions to market based on preliminary or biomarker evidence. However, companies are required to conduct a confirmatory study of a drug’s effectiveness. If these trials fail, the drug’s indication should be removed from FDA-approved labeling.

Despite this regulatory process, the study found that products with other approved uses can still be prescribed “off-label” for indications that have been withdrawn. Researchers examined trends in cancer drug usage after the failure of confirmatory trials and subsequent removal of accelerated approval indications. Their findings suggest that oncologists responded quickly to negative trial results, leading to a decrease in their use even though they remained available for off-label prescribing. This trend may reflect oncologists’ diligence in incorporating new clinical data into their practice or insurers’ decisions to limit coverage for ineffective treatments, the researchers say.

One exception noted in the study was romidepsin, a drug that continued to be used for its withdrawn indication. Researchers speculated that its continued use may be due to evidence of efficacy in certain subtypes of peripheral T-cell lymphoma, a rare and heterogeneous condition. However, the study also acknowledged several limitations, including a focus on a commercially insured population and an inability to isolate regulatory events from other factors affecting drug usage, such as the approval of alternative therapies.

Another major concern raised by the researchers was the delay between a drug’s accelerated approval, the publication of negative trial results, and the eventual removal of its indication from FDA labeling. This lag means that patients may be exposed to treatments that ultimately prove ineffective or potentially unsafe for extended periods. They emphasized the need for stricter enforcement of postapproval studies and more timely regulatory actions to protect patients.

The findings add to ongoing discussions about reforming FDA’s accelerated approval pathway to ensure that only effective medications remain available to patients. With the program under increased scrutiny, regulators may face growing pressure to ensure confirmatory trials are expedited and take swifter action on drugs that fail to meet clinical efficacy standards.